Qi Wang

Cooley advised D3 Bio – an emerging global biotechnology company that focuses on discovery, development and registration of innovative cancer drugs – on the close of its $62 million Series A+ financing.

Cooley advised HighLight Capital (HLC) on the close of its flagship HLC USD Fund IV at approximately $550 million.

Cooley advised Qiming Venture Partners, a leading venture capital firm in China, on the closing of its oversubscribed Qiming Venture Partners Fund VIII with $2.5 billion in committed capital. Lawyers Jordan Silber, Jingyi Xu, Qi Wang, Sheryl Dai and Hongbo Robert Bao led the Cooley team advising Qiming Venture Partners.

Cooley advised Source Code Capital, a leading Chinese venture capital firm, on the closing of its $1 billion fund, which received backing from both new and old investors. Partners Xun Zeng and Jingyi Xu led the Cooley team advising Source Code Capital.

Cooley advised Gaorong Capital on the oversubscribed closing of its fifth flagship US dollar fund at $1.15 billion, bringing the firm’s assets under management to about $4 billion. Lawyers Jordan Silber, Xun Zeng and Jingyi Xu led the Cooley team advising Gaorong.